For its part, the Aspire-AECC project. To improve the survival of liver cancer patients by combining immunotherapy and surgery, 8 million euros have been allocated for a period of six years. Its managers are Josep M. Llovet from Clínic-Idibaps Hospital in Barcelona and José R. Bustelo from the Center for Cancer Research of Salamanca (CSIC-University of Salamanca), who will conduct clinical trials of immunotherapy before and after surgery, and 15 hospital centers will be involved. In addition, 10 basic and translational research centers will participate.
Advertising
Ramon Reyes , president of the AECC, explained that this initiative was born “because cancer generates inequities . And this lack of equity is addressed by providing targeted and specific assistance to these types of cancer “. Isabelle Orbe , CEO of the AECC Science Foundation, noted that this contribution of funds “will have an impact by coordinating and making knowledge and survivorship available anywhere . Thus, the appeal supports the creation of research and clinical environments. The goal is what comes out of the lab, reaches people.
